Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort.
Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort.
复制标题
DOI：
10.1016/j.fertnstert.2013.08.008
复制
发表时间：
2013-12
影响因子：
6.7
通讯作者：
Brinton, Louise A.
中科院分区：
文献类型：
--
作者：
Trabert, Britton;Lamb, Emmet J.;Scoccia, Bert;Moghissi, Kamran S.;Westhoff, Carolyn L.;Niwa, Shelley;Brinton, Louise A.
探讨促排卵药物与卵巢癌的关系。回顾性队列研究，自首次报告以来进行了额外随访。五大生殖内分泌实践。在1965年至1988年期间在美国五个临床地点评估不孕症的9，825名妇女的回顾性队列中，随访至2010年，我们检查了促排卵药物与卵巢癌的关系（n = 85）。没有。卵巢癌的风险率比（RR）和95%置信区间（CI）。在评估不孕症的妇女中，卵巢癌风险与曾经使用过克罗米芬（CC）没有关联（调整后RR 1.34，95% CI 0.86-2.07）或促性腺激素（RR 1.00，95% CI 0.48-2.08），没有证据表明几个更详细的使用亚组中的任何一个与风险增加相关，但有一个例外：与未使用CC的妇女相比，使用CC并保持未妊娠的妇女确实表现出比成功怀孕的妇女高得多的风险（分别为RR 3.63，95%CI 1.36-9.72 vs. RR 0.88，95%CI 0.47-1.63）。我们的总体结果令人放心，并与其他研究一致。CC使用和卵巢癌之间的关联的原因持续未经妊娠妇女仍有待确定。鉴于大量且越来越多的妇女接受促排卵药物治疗，应进一步监测未孕妇女中卵巢癌风险增加的情况。
To examine the relationship of ovulation-inducing drugs and ovarian cancer. Retrospective cohort study, with additional follow-up since initial report. Five large reproductive endocrinology practices. In a retrospective cohort of 9,825 women evaluated for infertility at five clinical sites in the United States between 1965 and 1988 with follow-up through 2010, we examined the relationship of ovulation-inducing drugs and ovarian cancer (n = 85). None. Hazard rate ratios (RR) and 95% confidence intervals (CI) for ovarian cancer. Among women evaluated for infertility, there was no association of ovarian cancer risk with ever use of clomiphene citrate (CC) (adjusted RR 1.34, 95% CI 0.86–2.07) or gonadotropins (RR 1.00, 95% CI 0.48–2.08) and no evidence that any of several more detailed subgroups of usage were related to an increased risk with one exception: women who used CC and remained nulligravid did demonstrate much higher risks than those who successfully conceived compared with nonusers (respectively, RR 3.63, 95% CI 1.36–9.72 vs. RR 0.88, 95% CI 0.47–1.63). Our overall results were reassuring and consistent with other studies. A reason for an association between CC use and ovarian cancer among persistently nulligravid women remains to be determined. Given the large and increasing number of women treated with ovulation-inducing drugs, the increased risk of ovarian cancer among the subset of women who remained nulligravid should be further monitored.
登录
查看更多内容
影响因子：
5
作者：
Calderon-Margalit, R.;Friedlander, Y.;Paltiel, O.
通讯作者：
Paltiel, O.
影响因子：
6.1
作者：
Doyle, P;Maconochie, N;Tan, SL
通讯作者：
Tan, SL
影响因子：
158.5
作者：
ROSSING, MA;DALING, JR;SELF, SG
通讯作者：
SELF, SG
影响因子：
8.8
作者：
Silva, I. dos Santos;Wark, P. A.;MacLean, A. B.
通讯作者：
MacLean, A. B.
影响因子：
3.8
作者：
Kurta, Michelle L.;Moysich, Kirsten B.;Diergaarde, Brenda
通讯作者：
Diergaarde, Brenda